eligibility_summary
Eligible: Adults or children with advanced/metastatic solid or hematologic cancer that has progressed after or lacks effective standard therapy, and has an actionable NGS-identified alteration matching an open DETERMINE arm, life expectancy ≥3 months, consent, measurable disease, baseline biopsy/blood, adequate performance status. Exclude: unresolved ≥Grade 2 AEs, uncontrolled illness/infection, pregnancy, other trials/anticancer therapy or <4-week/5 half-life washout, unstable brain mets, or other investigator concerns.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
DETERMINE (NCT05722886) is a tumor-agnostic umbrella/basket platform testing licensed targeted therapies in rare cancers or common cancers with rare actionable alterations. Arms and mechanisms: 1) Alectinib—oral small-molecule ALK tyrosine kinase inhibitor, blocks ALK-driven signaling (MAPK/PI3K) in ALK+ tumors. 2) Atezolizumab—anti–PD-L1 monoclonal antibody immune checkpoint inhibitor, reactivates T cells in high TMB, MSI-H, or CMMRD tumors (targets PD-1/PD-L1 axis on tumor/immune cells). 3) Entrectinib—oral small-molecule TKI of ROS1 (also NTRK/ALK), inhibits ROS1 fusion signaling. 4) Trastuzumab + pertuzumab—HER2-targeted monoclonal antibodies, block HER2 signaling and dimerization, mediate ADCC in HER2-amplified/activating-mutant tumors. 5) Vemurafenib + cobimetinib—BRAF inhibitor + MEK inhibitor, suppress MAPK/ERK pathway in BRAF V600 tumors. 6) Capmatinib—oral small-molecule MET inhibitor, blocks MET/HGF signaling in MET-dysregulated cancers.